GALAPAGOS

Their core work

Galapagos is a Belgian clinical-stage biopharmaceutical company focused on discovering and developing small molecule medicines for diseases with high unmet medical need. In EU research projects they contribute as an industry anchor, bringing drug discovery platforms, compound libraries, and translational expertise to academically-led consortia. Their most substantive H2020 engagement is in cystic fibrosis — specifically personalised treatments for patients with ultra-rare CFTR gene mutations, working alongside clinical and academic partners on patient stratification using intestinal organoid models. As a large private company, they provide the kind of validated drug development infrastructure that converts academic findings into viable clinical candidates.

What they specialise in

How they've shifted over time

Galapagos's early H2020 presence (2016) was peripheral — a third-party industrial partner in an MSCA infectious disease training network, with no project-specific keywords recorded for their contribution. By 2018 their engagement deepened and sharpened considerably: they joined HIT-CF as a full participant with a highly specific scientific focus on cystic fibrosis, intestinal organoids, and paediatric patients. The trajectory is a clear narrowing from broad industrial observer to committed research partner in a defined therapeutic niche — rare respiratory and genetic disease.

Galapagos is deepening commitment to rare genetic disease research, making them a natural fit for future consortia centred on CFTR biology, organoid-based drug screening, or paediatric precision medicine.

How they like to work

Galapagos consistently joins as a non-leading partner — they have never coordinated an H2020 project — which reflects the standard pharma model of contributing industrial assets (compounds, platforms, regulatory know-how) without taking on grant management or administrative project leadership. They gravitate toward large consortia: two projects produced 32 unique partners across 12 countries, signalling comfort in complex multi-stakeholder environments. For prospective collaborators, this means Galapagos brings credibility and a real drug development pipeline but will not drive the proposal or project management.

Galapagos has worked with 32 unique consortium partners across 12 countries through only two projects, reflecting their integration into large pan-European clinical and academic networks. Their footprint spans multiple EU member states, consistent with participation in multi-site rare disease clinical research consortia.

What sets them apart

As one of Europe's leading clinical-stage biotechs with a proprietary drug discovery platform, Galapagos brings something academic groups rarely have: validated compounds, industrial screening infrastructure, and a clear path from a research finding to a clinical candidate. Their CF expertise is deep and specific — intestinal organoid models are a sophisticated patient stratification tool, and active participation in HIT-CF signals genuine scientific engagement rather than nominal industry presence. For rare disease consortia seeking an industry anchor with regulatory experience and an active CF pipeline, Galapagos is a high-value partner.

Highlights from their portfolio

• HIT-CF
  A long-running (2018–2025) personalised medicine project targeting ultra-rare CFTR mutations in paediatric patients via intestinal organoid drug response modelling — one of the most scientifically specific CF programmes in H2020.
• ND4ID
  An MSCA Innovative Training Network on new infectious disease diagnostics where Galapagos participated as a third-party industrial partner, reflecting an early cross-disease engagement beyond their CF core.